Fate Therapeutics, Inc. (FATE)
After hours:
| Previous close | 5.27 |
| Open | 5.27 |
| Bid | 5.03 x 400 |
| Ask | 5.05 x 100 |
| Day's range | 4.98 - 5.34 |
| 52-week range | 1.63 - 8.83 |
| Volume | |
| Avg. volume | 2,816,011 |
| Market cap | 573.466M |
| Beta (5Y monthly) | 1.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.64 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.80 |
ZacksFate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
GlobeNewswireFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET. A live webcast
- GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved
